Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacture and commercialisation of endomicroscopic digital imaging technology solutions

[Optiscan @Optiscan_]

Good coverage in The West and @BullsNBearsWA today.

Learn more: https://t.co/pF029fqeWZ

#digitalpatholology #imageguidedsurgery #singlecellimaging #imaginethepossibilities #thewest #optiscanimaging #invivage

[Bulls N' Bears @BullsNBearsWA]

A money trail is forming behind @Optiscan technology-based mission to tackle the scourge of #cancer, with revenue starting to stream into the company’s coffers from the lucrative Chinese health sector.

$OIL #BULLSNBEARSWA #ASX #MedTech @westaustralian

https://t.co/dSly21TfQe

[Optiscan @Optiscan_]

Delighted to be attending #CellBio23 in Boston. Looking forward to connecting with attendees and establishing new connections for our unique handheld, slide-free, non-destructive #viewnvivo single-cell imaging technology.
#seelifeconnected #CellBiology #CellBio #optiscanimaging

[Optiscan @Optiscan_]

Learn more about our business, technology, and get glimpse into the future of digital pathology and precision surgery in this expert report from @stockhead

#optiscanimaging #digitalpathology #Robotics

[Stockhead @StockheadAU]

Optiscan has developed a hand-held pen-like device for digital biopsies that harnesses confocal laser endo-microscopy to produce hi-res images. | #health #stocks #biotech #medicine #ASX https://t.co/39jOaJ203L

[Optiscan @Optiscan_]

Delighted to be collaborating with Design + Industry in developing our new product portfolio. With 260 industry awards over 35 years, we look forward to perfecting our new devices for clinicians, health systems and patients.
#imaginethepossibilities #digitalpathology

[Optiscan @Optiscan_]

Optiscan Imaging Ltd wishes all our US colleagues, clinicians, partners, friends, and their families a wonderful #Thanksgiving.

We hope your day is filled with warmth, happiness, and the company of those closest to you.

[Optiscan @Optiscan_]

@StockheadAU For further information on our technology, please visit https://t.co/pF029fqeWZ & follow our media channels for regular updates.

[Optiscan @Optiscan_]

Following news about a global shortage of pathologists, we have been featured in a special report by @StockheadAU today.

#optiscanimaging #digitalpathology #imaginethepossibilities

Read: https://t.co/1UipQ73iuF

[Optiscan @Optiscan_]

Optiscan Imaging Ltd has released its Quarterly Report and Appendix 4C for the quarter ended 30 September 2023.

Read: https://t.co/N5bshE8ZmX

#optiscanimaging #asx

[Optiscan @Optiscan_]

Delighted to announce a special report on our company in #stockhead today.

Learn more: https://t.co/pF029fqeWZ

#optiscanimaging #digitalpathology #imaginethepossibilities

https://t.co/SCPfVQk9dX

[Optiscan @Optiscan_]

Delighted to welcome Brendan Fafiani as our new Chief Operating Officer. Mr Fafiani will lead operations at our Melbourne headquarters, our operational planning, commercialisation strategy, customer and development efforts.

Read: https://t.co/N5bshE8ZmX

#optiscanimaging #ASX

[Optiscan @Optiscan_]

@BullsNBearsWA @OptiScan For further updates follow us at @Optiscan_. To learn more visit https://t.co/pF029fqeWZ.

[Optiscan @Optiscan_]

@westaustralian Follow @Optiscan_ for regular updates or visit https://t.co/pF029fqeWZ to learn more.

[Optiscan @Optiscan_]

Delighted to announce the appointment of Tim Rowe and Shayra Leon as our new Business Development Managers for North America.

Read: https://t.co/N5bshE8ZmX

#asx #optiscanimaging

[Optiscan @Optiscan_]

Pleased to announce interim readout on our Breast Cancer Intraoperative Assessment Study, revealing excellent correlation between our real-time #CLE imaging and traditional histological analysis.

Read more: https://t.co/4naYd0K6Nj

#optiscanimaging #digitalpathology #asx

[Optiscan @Optiscan_]

Further coverage by @westaustralian. Visit https://t.co/pF029fqeWZ to learn more.

[The West Australian @westaustralian]

Optiscan Imaging has rounded out a dynamic year with a whopping 66 per cent revenue boost to nearly $1.7 million following the sale of its ViewnVivo research device to an American pharmaceutical company. #BULLSNBEARSWA https://t.co/kJxhsJK7jJ

[Bulls N' Bears @BullsNBearsWA]

#Medtech company @Optiscan_ has rounded out a dynamic year with a whopping 66 per cent revenue boost to nearly $1.7 million following the sale of its #ViewnVivo research device to an American pharmaceutical company.

$OIL @westaustralian @prolucid

https://t.co/wVAIZHR8dq

[Optiscan @Optiscan_]

@BullsNBearsWA @westaustralian @prolucid Please visit https://t.co/pF029fqeWZ to learn more

[Optiscan @Optiscan_]

We have released our Annual Report FY23, with revenues increasing to $1.68m (+66%) and net cash outflows decreasing from $3.8m to $3.2m. We thank all our collaborators, shareholders, and employees for their ongoing support & look forward to FY24.
https://t.co/N5bshE8ZmX

[Bulls N' Bears @BullsNBearsWA]

#Medtech company @Optiscan_ secures $16.7m research and development funding

$OIL #OptiscanImaging #BULLSNBEARSWA #ASX #3DImaging #SaMD #DigitalPathology #ProlucidTechnologies

https://t.co/YIMlz88ONG

[Optiscan @Optiscan_]

Further coverage in Bulls N' Bears today
#digitalpathology #imaginethepossibilities #AI #telepathology

[Bulls N' Bears @BullsNBearsWA]

#Medtech company @Optiscan_ secures $16.7m research and development funding

$OIL #OptiscanImaging #BULLSNBEARSWA #ASX #3DImaging #SaMD #DigitalPathology #ProlucidTechnologies

https://t.co/YIMlz88ONG